The company#39;s wholly owned subsidiary, “Cipla USA Inc has signed a worldwide licensing agreement (except for East Asia) with MEDRx Company Ltd to further develop and commercialise MRX-4TZT, a Tizanidine1 patch for the management of spasticity”, Cipla said in a filing to BSE.